摘要
目的评价培美曲塞联合顺铂一线治疗晚期非小细胞肺癌(NSCLC)的临床疗效和毒副反应。方法 48例初治晚期NSCLC接受培美曲塞联合顺铂化疗,接受2个周期化疗后评价临床疗效和毒副反应。结果 48例中,PR 13例,SD 15例,PD 20例,有效率27.08%,临床获益率58.33%。主要毒副反应为骨髓抑制、胃肠道反应和皮肤过敏。结论培美曲塞联合顺铂一线治疗晚期NSCLC疗效可靠,毒副反应轻。
Objective To observe the clinical efficacy and toxicities of pemetrexed combined with cisplatin as the first-line regimen in the treatment of advanced non-small-cell lung cancer（NSCLC）.Methods Forty-eight patients with advanced NSCLC received the pemetrexed combined with cisplatin chemotherapy,the clinical efficacy and toxicities were evaluated after 2 cycles of chemotherapy.Results Of all the 48 cases,the 13 cases with PR,the 15 cases with SD,the 20 cases with PD,the effective rate was 27.08%,and the clinical benefit rate was 58.33%.The main toxicities were marrow suppression,gastrointestinal reaction and skin allergy.Conclusion The pemetrexed combined with cisplatin as the first-line regimen in the treatment of advanced NSCLC has reliable efficacy and fewer toxicities.
出处
《肿瘤基础与临床》
2011年第4期298-300,共3页
journal of basic and clinical oncology
关键词
培美曲塞
顺铂
晚期非小细胞肺癌
化疗
pemetrexed
cisplatin
advanced non-small-cell lung cancer
chemotherapy
